Low molecular weight heparin promotes the PPAR pathway by protecting the glycocalyx of cells to delay the progression of diabetic nephropathy

Diabetic nephropathy (DN) is one of the most important comorbidities for diabetic patients, which is the main factor leading to end-stage renal disease. Heparin analogs can delay the progression of DN, but the mechanism is not fully understood. In this study, we found that low molecular weight hepar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of biological chemistry 2024-08, Vol.300 (8), p.107493, Article 107493
Hauptverfasser:	Zhang, Bin, Bu, Changkai, Wang, Qingchi, Chen, Qingqing, Shi, Deling, Qiu, Hongyan, Wang, Zhangjie, Liu, Jian, Wang, Zhe, Zhang, Qunye, Chi, Lianli
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Collection: Cell Biology Diabetic Nephropathies - drug therapy Diabetic Nephropathies - metabolism Diabetic Nephropathies - pathology diabetic nephropathy Disease Progression endocytosis FABP1 Fatty Acid-Binding Proteins - genetics Fatty Acid-Binding Proteins - metabolism Glucuronidase - genetics Glucuronidase - metabolism Glycocalyx - drug effects Glycocalyx - metabolism heparan sulfate Heparin, Low-Molecular-Weight - pharmacology Heparitin Sulfate - metabolism Humans low molecular weight heparin Mice Peroxisome Proliferator-Activated Receptors - metabolism PPAR pathway Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!